Complement component 5

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Complement component 5
C5.png
PDB rendering based on 3cu7.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols C5 ; C5D; C5a; C5b; CPAMD4; ECLZB
External IDs OMIM120900 MGI96031 HomoloGene20412 GeneCards: C5 Gene
RNA expression pattern
PBB GE C5 205500 at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 727 15139
Ensembl ENSG00000106804 ENSMUSG00000026874
UniProt P01031 P06684
RefSeq (mRNA) NM_001735 NM_010406
RefSeq (protein) NP_001726 NP_034536
Location (UCSC) Chr 9:
123.71 – 123.81 Mb
Chr 2:
34.98 – 35.06 Mb
PubMed search [1] [2]

Complement component 5 is a protein that in humans is encoded by the C5 gene.[1]

Complement component 5 is involved in the complement system. It is cleaved into C5a and C5b:

Deficiency is thought to cause Leiner's disease.

Function[edit]

Complement component 5 is the fifth component of complement, which plays an important role in inflammatory and cell killing processes. This protein is composed of alpha and beta polypeptide chains that are linked by a disulfide bridge. An activation peptide, C5a, which is an anaphylatoxin that possesses potent spasmogenic and chemotactic activity, is derived from the alpha polypeptide via cleavage with a convertase. The C5b macromolecular cleavage product can form a complex with the C6 complement component, and this complex is the basis for formation of the membrane attack complex, which includes additional complement components.[1]

Clinical significance[edit]

Mutations in this gene cause complement component 5 deficiency, a disease where patients show a propensity for severe recurrent infections. Defects in this gene have also been linked to a susceptibility to liver fibrosis and to rheumatoid arthritis.[1]

Therapeutic applications[edit]

The drug eculizumab prevents cleavage of C5 into C5a and C5b.[3]

Complement system pathway[edit]

Membrane attack complex. Some labels are in Polish.


References[edit]

  1. ^ a b c "Entrez Gene: complement component 5". 
  2. ^ Immunology at MCG 1/phagocyt
  3. ^ Dubois E, Cohen A (2009). "Eculizumab". Br J Clin Pharmacol 68 (3): 318–319. doi:10.1111/j.1365-2125.2009.03491.x. PMC 2766470. PMID 19740388. 

Further reading[edit]

  • Tack BF, Morris SC, Prahl JW (1979). "Fifth component of human complement: purification from plasma and polypeptide chain structure". Biochemistry 18 (8): 1490–7. doi:10.1021/bi00575a016. PMID 106884. 
  • Fernandez HN, Hugli TE (1978). "Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a". J. Biol. Chem. 253 (19): 6955–64. PMID 690134. 
  • DiScipio RG (1992). "Formation and structure of the C5b-7 complex of the lytic pathway of complement". J. Biol. Chem. 267 (24): 17087–94. PMID 1387399. 
  • Haviland DL, Haviland JC, Fleischer DT, et al. (1991). "Complete cDNA sequence of human complement pro-C5. Evidence of truncated transcripts derived from a single copy gene". J. Immunol. 146 (1): 362–8. PMID 1984448. 
  • Bohnsack JF, Mollison KW, Buko AM, et al. (1991). "Group B streptococci inactivate complement component C5a by enzymic cleavage at the C-terminus". Biochem. J. 273 (Pt 3): 635–40. PMC 1149811. PMID 1996961. 
  • Lundwall AB, Wetsel RA, Kristensen T, et al. (1985). "Isolation and sequence analysis of a cDNA clone encoding the fifth complement component". J. Biol. Chem. 260 (4): 2108–12. PMID 2579066. 
  • Zuiderweg ER, Fesik SW (1989). "Heteronuclear three-dimensional NMR spectroscopy of the inflammatory protein C5a". Biochemistry 28 (6): 2387–91. doi:10.1021/bi00432a008. PMID 2730871. 
  • Zuiderweg ER, Nettesheim DG, Mollison KW, Carter GW (1989). "Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data". Biochemistry 28 (1): 172–85. doi:10.1021/bi00427a025. PMID 2784981. 
  • Haefliger JA, Tschopp J, Vial N, Jenne DE (1989). "Complete primary structure and functional characterization of the sixth component of the human complement system. Identification of the C5b-binding domain in complement C6". J. Biol. Chem. 264 (30): 18041–51. PMID 2808363. 
  • Wetsel RA, Lemons RS, Le Beau MM, et al. (1988). "Molecular analysis of human complement component C5: localization of the structural gene to chromosome 9". Biochemistry 27 (5): 1474–82. doi:10.1021/bi00405a012. PMID 3365401. 
  • Zuiderweg ER, Mollison KW, Henkin J, Carter GW (1988). "Sequence-specific assignments in the 1H NMR spectrum of the human inflammatory protein C5a". Biochemistry 27 (10): 3568–80. doi:10.1021/bi00410a007. PMID 3408713. 
  • Stewart JL, Kolb WP, Sodetz JM (1987). "Evidence that C5b recognizes and mediates C8 incorporation into the cytolytic complex of complement". J. Immunol. 139 (6): 1960–4. PMID 3624872. 
  • Buhl AM, Osawa S, Johnson GL (1995). "Mitogen-activated protein kinase activation requires two signal inputs from the human anaphylatoxin C5a receptor". J. Biol. Chem. 270 (34): 19828–32. doi:10.1074/jbc.270.34.19828. PMID 7649993. 
  • Babkina IN, Seregin SV, Daniliuk NK, et al. (1995). "[Chemico-enzymatic synthesis, cloning and expression of a gene for an analog of human anaphylatoxin C5a]". Bioorg. Khim. 21 (5): 359–64. PMID 7661861. 
  • Wang X, Fleischer DT, Whitehead WT, et al. (1995). "Inherited human complement C5 deficiency. Nonsense mutations in exons 1 (Gln1 to Stop) and 36 (Arg1458 to Stop) and compound heterozygosity in three African-American families". J. Immunol. 154 (10): 5464–71. PMID 7730648. 
  • Oppermann M, Götze O (1995). "Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors". Immunology 82 (4): 516–21. PMC 1414921. PMID 7835913. 
  • Süsal C, Kirschfink M, Kröpelin M, et al. (1994). "Complement activation by recombinant HIV-1 glycoprotein gp120". J. Immunol. 152 (12): 6028–34. PMID 7911492. 
  • Arribas J, Arizti P, Castaño JG (1994). "Antibodies against the C2 COOH-terminal region discriminate the active and latent forms of the multicatalytic proteinase complex". J. Biol. Chem. 269 (17): 12858–64. PMID 8175701. 
  • Süsal C, Kirschfink M, Kröpelin M, et al. (1996). "Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120". Blood 87 (6): 2329–36. PMID 8630395. 
  • Ames RS, Li Y, Sarau HM, et al. (1996). "Molecular cloning and characterization of the human anaphylatoxin C3a receptor". J. Biol. Chem. 271 (34): 20231–4. doi:10.1074/jbc.271.34.20231. PMID 8702752. 
  • Fredslund F, Laursen NS, Roversi P et al. (2008). "Structure of and influence of a tick complement inhibitor on human complement component 5". Nat Immunol. 9 (7): 753–60. doi:10.1038/ni.1625. PMID 18536718. 

External links[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.